MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Alkermes PLC

Fechado

SetorSaúde

28.88 -0.21

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.86

Máximo

29.08

Indicadores-chave

By Trading Economics

Rendimento

-124M

22M

Vendas

-123M

307M

P/E

Médio do Setor

13.624

40.527

EPS

0.291

Margem de lucro

7.329

Funcionários

1,800

EBITDA

-168M

14M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+38.65% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.1B

4.7B

Abertura anterior

29.09

Fecho anterior

28.88

Sentimento de Notícias

By Acuity

50%

50%

115 / 375 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Alkermes PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jul. de 2025, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

4 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 15:57 UTC

Conversa de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 de jul. de 2025, 15:49 UTC

Conversa de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 de jul. de 2025, 15:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Received All Required Authorizations

4 de jul. de 2025, 15:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole: Agreement Was Announced on Dec. 19

4 de jul. de 2025, 15:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 de jul. de 2025, 15:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 de jul. de 2025, 14:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 de jul. de 2025, 13:53 UTC

Conversa de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 de jul. de 2025, 13:41 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de jul. de 2025, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 de jul. de 2025, 12:37 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 de jul. de 2025, 12:30 UTC

Conversa de Mercado

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 de jul. de 2025, 12:15 UTC

Conversa de Mercado

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 de jul. de 2025, 12:13 UTC

Conversa de Mercado

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 de jul. de 2025, 12:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Alkermes PLC Previsão

Preço-alvo

By TipRanks

38.65% parte superior

Previsão para 12 meses

Média 40 USD  38.65%

Máximo 46 USD

Mínimo 30 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Alkermes PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

8

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

27.95 / 30.91Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

115 / 375 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.